Viatris Inc. announced a definitive agreement to sell its equity stake in Biocon Biologics Limited to Biocon Limited for $815 million. The deal, comprised of $400 million in cash and $415 million in newly issued equity shares of Biocon, will accelerate the expiration of biosimilars non-compete restrictions for Viatris. The transaction is expected to finalize in the first quarter of 2026.

晖致

<p>Viatris Inc. 宣布与 Biocon Limited 达成一项最终协议，以 8.15 亿美元的价格出售其在 Biocon Biologics Limited 的股权。该交易包括 4 亿美元现金和 4.15 亿美元的新发行 Biocon 股份，将加速 Viatris 生物类似药的非竞争限制的到期。该交易预计将在 2026 年第一季度完成</p>

晖致将以 8.15 亿美元的价格把其在 Biocon Biologics 的股权出售给 Biocon